<?xml version="1.0" encoding="UTF-8"?>
<p>Ensuing studies have confirmed and built upon these findings [
 <xref rid="C19" ref-type="bibr">19</xref>]. AT
 <sub>1</sub> receptor blockade upregulates ACE2 through a negative feedback mechanism, and serve as a lung-protective mechanism through the increased conversion of Ang II to Ang-(1–7), effectively blunting pulmonary injury from the virus [
 <xref rid="C50" ref-type="bibr">50</xref>]. These findings have led investigators to posit that the ACE2/Ang-(1–7) pathway may serve as a therapeutic target to combat the pathological effects of Ang II [
 <xref rid="C74" ref-type="bibr">74</xref>]. To that end, there is already at least one trial of recombinant human ACE2 therapy for the treatment of COVID-19 that attempts to leverage this relationship and mitigate downstream lung injury [
 <xref rid="C23" ref-type="bibr">23</xref>, 
 <xref rid="C35" ref-type="bibr">35</xref>].
</p>
